Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217425 | 1.00 | NCF1 (0.33) | NCF1CRHR1GRM5TAS1R3TAS1R1 | |
| SCHEMBL7224417 | 0.79 | LMNA (0.33) | GRM5 | |
| SCHEMBL7222310 | 0.79 | LMNA (0.33) | GRM5 | |
| SCHEMBL7478626 | 0.79 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL7472507 | 0.79 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL7478036 | 0.75 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL23547380 | 0.74 | NR4A2 (0.49) | — | |
| SCHEMBL7624509 | 0.69 | CRHR1 (0.54) | CRHR1 | |
| Hydrochloric Acid SCHEMBL7624850 | 0.69 | LMNA (0.34) | CRHR1 | |
| SCHEMBL5845050 | 0.68 | CRHR1 (0.37) | CRHR1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6525056-B2 | A fused nitrogen containing heterocyclic compound useful for treating psychiatric and neurological disorders, anxiety, post-traumatic stress, supranuclear palsy, feeding, immunological, cardiovascular and hypersensitivity disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6448261-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC AND NEUROLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1012151-B1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-09-27 | — | — | US | disclosed |
| US-6245769-B1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders | DUPONT PHARMACEUTICALS COMPANY | 2001-06-12 | — | — | US | disclosed |
| US-6107300-A | CORTICOTROPIN RELEASING FACTOR ANTAGONIST; PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS (US) | 2000-08-22 | — | — | US | disclosed |
| EP-1012151-A1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | Dupont Pharmaceuticals Company (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999011643-A1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | CRH, CRHR1, CRHR2 | NCF1 1846/4885CRHR1 2/4885GRM5 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.